Activation of the mTORC1 and STAT3 pathways promotes the malignant transformation of colitis in mice

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1873-1880

  He, Zhen ^a   He, Xiaosheng ^a   Chen, Zexian ^a   Ke, Jia ^a   He, Xiaowen ^a   Yuan, Ruixue ^a   Cai, Zerong ^a   Chen, Xiuting ^a   Wu, Xiaojian ^a   Lan, Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colitis Associated colorectal cancer; Inflammation; MTORC1; STAT3

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; AZOXYMETHANE; CYTOKINE; DEXTRAN SULFATE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; STAT3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLORECTAL NEOPLASMS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84907286255     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3421     Document Type: Article

References (46)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
2. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-Analysis. Gut 48: 526-535, 2001.
3. Gillen CD, Walmsley RS, Prior P, Andrews HA and Allan RN: Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35: 1590-1592, 1994.
4. Saleh M and Trinchieri G: Innate immune mechanisms of colitis and colitis-Associated colorectal cancer. Nat Rev Immunol 11: 9-20, 2011.
5. Rhodes JM: Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet 347: 40-44, 1996.
6. Rutter M, Saunders B, Wilkinson K, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459, 2004.
7. Strimpakos AS, Karapanagiotou EM, Saif MW and Syrigos KN: The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35: 148-159, 2009.
8. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
9. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
10. Delgoffe GM and Powell JD: mTOR: taking cues from the immune microenvironment. Immunology 127: 459-465, 2009.
11. Magnuson B, Ekim B and Fingar DC: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1-21, 2012.
12. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD and Pearson RB: Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25: 209-226, 2007.
13. Duvel K, Yecies JL, Menon S, et al: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183, 2010.
14. Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361, 2005.
15. Sarbassov DD, Ali SM, Sengupta S, et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168, 2006.
16. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
17. Thiem S, Pierce TP, Palmieri M, et al: mTORC1 inhibition restricts inflammation-Associated gastrointestinal tumorigenesis in mice. J Clin Invest 123: 767-781, 2013.
18. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
19. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15: 103-113, 2009.
20. Chumanevich AA, Poudyal D, Cui X, et al: Suppression of colitisdriven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 31: 1787-1793, 2010.
21. Namba R, Young LJ, Abbey CK, et al: Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12: 2613-2621, 2006.
22. Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51, 2007.
23. Park E, Park J, Han SW, et al: NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol 40: 1259-1266, 2012.
24. Farraye FA, Odze RD, Eaden J and Itzkowitz SH: AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138: 746-774.e4, 2010.
25. Gupta RB, Harpaz N, Itzkowitz S, et al: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133: 1099-1105, 2007.
26. Sobala A, Herbst F, Novacek G and Vogelsang H: Colorectal carcinoma and preceding fistula in Crohn's disease. J Crohns Colitis 4: 189-193, 2010.
27. Laukoetter MG, Mennigen R, Hannig CM, et al: Intestinal cancer risk in Crohn's disease: a meta-Analysis. J Gastrointest Surg 15: 576-583, 2011.
28. van Staa TP, Card T, Logan RF and Leufkens HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54: 1573-1578, 2005.
29. Rubin DT, LoSavio A, Yadron N, Huo D and Hanauer SB: Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4: 1346-1350, 2006.
30. Slomovitz BM and Coleman RL: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18: 5856-5864, 2012.
31. Lauring J, Park BH and Wolff AC: The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Cancer Netw 11: 670-678, 2013.
32. Lee YK, Park SY, Kim YM, et al: Suppression of mTOR via Akt-dependent and-independent mechanisms in selenium.treated colon cancer cells: involvement of AMPKα1. Carcinogenesis 31: 1092-1099, 2010.
33. Zhang DM, Liu JS, Deng LJ, et al: Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 34: 1331-1342, 2013.
34. Smrz D, Kim MS, Zhang S, et al: mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 118: 6803-6813, 2011.
35. Fox R, Nhan TQ, Law GL, Morris DR, Liles WC and Schwartz SM: PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. Embo J 26: 505-515, 2007.
36. Kawauchi K, Ihjima K and Yamada O: IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 174: 5261-5269, 2005.
37. Donahue AC and Fruman DA: Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J Immunol 170: 5851-5860, 2003.
38. Powell JD and Delgoffe GM: The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33: 301-311, 2010.
39. Memmott RM and Dennis PA: The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res 16: 4-10, 2010.
40. Ma J, Meng Y, Kwiatkowski DJ, et al: Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120: 103-114, 2010.
41. Farkas S, Hornung M, Sattler C, et al: Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis 21: 747-753, 2006.
42. Deng L, Zhou JF, Sellers RS, et al: A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-Associated tumorigenesis. Am J Pathol 176: 952-967, 2010.
43. Wu Y and Zhou BP: TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102: 639-644, 2010.
44. Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512, 2005.
45. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15: 103-113, 2009.
46. Lippitz BE: Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14: e218-e228, 2013.